CN102657842A - Medicinal composition with function of increasing bone density and application thereof - Google Patents
Medicinal composition with function of increasing bone density and application thereof Download PDFInfo
- Publication number
- CN102657842A CN102657842A CN2012101517622A CN201210151762A CN102657842A CN 102657842 A CN102657842 A CN 102657842A CN 2012101517622 A CN2012101517622 A CN 2012101517622A CN 201210151762 A CN201210151762 A CN 201210151762A CN 102657842 A CN102657842 A CN 102657842A
- Authority
- CN
- China
- Prior art keywords
- extract
- bone density
- percent
- bone
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention discloses a medicinal composition with a function of increasing bone density. The medicinal composition is an oral preparation which is prepared from the following active ingredients in percentage by weight: 10-40 percent of calcium carbonate, 5-30 percent of D-Glucosamine hydrochloride, 5-20 percent of chondroitin sulfate, 5-30 percent of epimedium extract, 3-10 percent of achyranthes bidentata extract and 3-15 percent of casein phosphopeptides. The medicinal composition is a Chinese medicinal preparation which contains no toxic medicinal crop, and has the characteristics of effect of increasing the bone intensity, obvious curative effect, low manufacturing cost, high curative effect, quick response and no toxic or side effect.
Description
Technical field
The present invention relates to the Chinese medicine health care product field, be specifically related to a kind of Chinese medicine preparation and method for preparing of bone density improving feature capability.
Background technology
Along with the aggravation of China's aged tendency of population, people's health care also will welcome new challenge.Be accompanied by human senility, the body bone metabolism begins to get muddled, and the balance between osteoblast and osteoclast effect is broken; Bone resorption is greater than bone formation; Cause bone ore deposit composition and bone matrix equal proportion and reduce, the osseous tissue microstructure is impaired, finally causes osteoporosis.Lumbar and back pain, spine malformation can be arranged, and the probability of fracture also rises significantly, seriously disturbed patient's quality of life, and the hazardness of osteoporotic fracture and refracture is bigger, has a strong impact on the quality of life of elderly population, causes a large amount of wastes of medical resource.Osteoporosis has become global public health problem.Bone density decline and osteoporosis are particularly serious in postclimacteric elderly woman, and better Therapeutic Method is not arranged except that controversies in hormone replacement in the elderly at present as yet.Therefore yet controversies in hormone replacement in the elderly can obviously increase the incidence rate of carcinoma of endometrium and breast carcinoma, demands developing a kind of health food of safe and effective bone density improving urgently.
Summary of the invention
The objective of the invention is in order to respond the demand of background technology, and a kind of good effect that provides and the pharmaceutical composition with bone density improving function that has no side effect.
To achieve these goals; The technical scheme that the present invention adopts is: a kind of pharmaceutical composition with bone density improving function is characterized in that said preparation is is the oral formulations that active ingredient is processed with calcium carbonate, glucosamine hydrochloride, chondroitin sulfate, Herba Epimedii extract, Radix Achyranthis Bidentatae extract, phosphopeptide caseinate; Wherein the active ingredient percentage by weight consists of: calcium carbonate 10-40%, glucosamine hydrochloride 5-30%, chondroitin sulfate 5-20%, Herba Epimedii extract 5-30%, Radix Achyranthis Bidentatae extract 3-10%, phosphopeptide caseinate 3-15%.
Preferred version of the present invention is; A kind of pharmaceutical composition with bone density improving function is characterized in that primary raw material consists of: calcium carbonate 20-50%, glucosamine hydrochloride 10-40%, chondroitin sulfate 10-30%, Herba Epimedii extract 10-40%, Radix Achyranthis Bidentatae extract 5-25%, phosphopeptide caseinate 10-30%.
The present invention is characterized in that wherein said oral formulations is that medically acceptable various dosage forms comprise tablet, capsule, granule or oral liquid.Chinese medicine active ingredient extract mixes, and processes tablet, capsule, granule, drop pill or oral liquid by conventional method and pharmaceutic adjuvant.
Described pharmaceutical composition has in bone density improving health care foods or the medicine in preparation to be used.
We are according to the dialectical Cheng Fang of Traditional Chinese medical theory, and the traditional Chinese medical science is thought kidney governing bones, and Herba Epimedii extract has the effect of kidney invigorating and YANG supporting in the side, and immune system, skeleton and reproductive system are all had tangible regulating action, can go into liver, kidney channel.Radix Achyranthis Bidentatae extract has invigorating the liver and kidney, and the effect of bone and muscle strengthening is used for soreness of waist and knee joint since ancient times, and muscles and bones is unable, goes into liver, kidney channel.And the calcium carbonate comparatively sure a kind of calcium complement agent that is effect of supplemented calcium; Glucosamine hydrochloride is chitin abundant hydrolysis preparation under the concentrated hydrochloric acid effect, and it is a kind of important derivatives of chitin, is the main component of chondroitin sulfate, and human body is had the important physical function.Can promote the synthetic of human body mucopolysaccharide, improve the viscosity of knuckle synovia, can improve the metabolism of articular cartilage, help the reparation of articular cartilage, have tangible anti-inflammatory analgesic action; Chondroitin sulfate has tangible close cartilage property, can preferentially get into cartilaginous tissue, the protection cartilage; Can moisture be sucked the proteoglycan intramolecularly, make the cartilage thickening, and increase IA synovial fluid amount; But releasing arthritis ache also, and be used to protect the joint as dietary supplement.Can significantly improve bone mineral content and bone density, reduce the serum alkaline phosphatase level, and can significantly improve the biomechanical parameter of femur.Can strengthen the II collagen mRNA and express and regenerating bone or cartilage, promote osteoblastic hypertrophy, promote new bone formation, the process of accelerated bone healing.Phosphopeptide caseinate and Ca
2+Affinity very strong, can be in PH7～8 o'clock and Ca
2+Form soluble complexes, thereby promote the absorption of calcium.Make a general survey of the present invention, all medicine compatibilities bring out the best in each other, and all flavor compatibilities are played the tranquilizing by nourishing the heart calmness altogether, the effect of relieving restlessness resolving depression that clears away heart-fire, thus reach the purpose of bone density improving.
The present invention compares with existing preparation, has following advantage, and pharmaceutical composition of the present invention is not for containing the Chinese medicine preparation of toxicity medical material, and it is obvious to have curative effect, and cost is low, curative effect is high, instant effect, the characteristics that have no side effect.
The specific embodiment
Through concrete embodiment technical scheme of the present invention is further described below, the embodiment that wherein gives an example only is to explanation of the present invention, and can not limit protection scope of the present invention by any way.
Embodiment 1
Prescription: calcium carbonate 200g, glucosamine hydrochloride 90 g, chondroitin sulfate 40 g, Herba Epimedii extract 70 g, Radix Achyranthis Bidentatae extract 60 g, phosphopeptide caseinate 37.5 g, magnesium stearate 2.5 g.Raw materials mix is even, sieves, and pours into capsule, makes capsule.
Embodiment 2
Prescription: calcium carbonate 250g, glucosamine hydrochloride 100 g, chondroitin sulfate 60 g, Herba Epimedii extract 80 g, Radix Achyranthis Bidentatae extract 70 g, phosphopeptide caseinate 45 g, magnesium stearate 3 g.Raw materials mix is even, adds suitable adjuvant dextrin, magnesium stearate, sieves, and tabletting makes tablet.
Embodiment 3
Prescription: calcium carbonate 150g, glucosamine hydrochloride 50 g, chondroitin sulfate 30 g, Herba Epimedii extract 50 g, Radix Achyranthis Bidentatae extract 45 g, phosphopeptide caseinate 35 g, the suitable adjuvant dextrin of adding, magnesium stearate, sieve, granulate, make granule.
Embodiment 4
Herba Epimedii extract obtains through following manner: Radix Salviae Miltiorrhizae adds 8-10 times of weight water decocting and boils 2-3 time, and during each 1-2, density is 1.16 extractum when being concentrated into 65 ℃, obtains Herba Epimedii extract.
The Radix Achyranthis Bidentatae conopsea extraction obtains through following manner: Radix Salviae Miltiorrhizae adds 8-10 times of weight water decocting and boils 2-3 time, and during each 1-2, density is 1.16 extractum when being concentrated into 65 ℃, obtains the Radix Achyranthis Bidentatae conopsea extraction.
Each raw material is prepared by following percentage by weight: oligofructose 10%, aloe full leaf dried powder 15%, Semen Pruni extract 45%, Radix Panacis Quinquefolii extract 25%.An amount of dextrin, magnesium stearate, raw materials mix is even, adds suitable adjuvant dextrin, magnesium stearate, sieves, and pours into capsule, makes capsule.
For ease of contrast, below embodiment is represented with form, each raw materials by weight meter, and all be equipped with an amount of adjuvant and make corresponding dosage form.
| Embodiment | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 |
| Calcium carbonate | 10 | 35 | 30 | 40 | 25 | 35 | 32 | 15 | 20 | 28 |
| Glucosamine hydrochloride | 30 | 15 | 10 | 5 | 20 | 25 | 16 | 22 | 32 | 28 |
| Chondroitin sulfate | 15 | 20 | 5 | 10 | 18 | 20 | 16 | 8 | 12 | 10 |
| Herba Epimedii extract | 20 | 30 | 5 | 10 | 40 | 15 | 35 | 25 | 9 | 18 |
| Radix Achyranthis Bidentatae extract | 3 | 10 | 8 | 5 | 6 | 8 | 10 | 3 | 7 | 9 |
| Phosphopeptide caseinate | 15 | 3 | 9 | 6 | 8 | 12 | 10 | 3 | 9 | 15 |
| Dosage form | Capsule | Tablet | Granule | Granule | Tablet | Oral liquid | Tablet | Capsule | Capsule | Oral liquid |
Preparation active ingredient quantitative criterion total saponins of the present invention is measured total flavones 0.02g/100g according to the method for " mensuration of total flavones in the health food " in " health food check and assessment technique standard " (version in 2003).
The oral dose that the present invention has the Chinese medicine preparation of bone density improving function is: 2-3g.30 days courses of treatment.
Pharmacological evaluation proves:
The SD female rats is as animal model after selecting the ovary castration for use, medicine in advance, the bone density and the bone calcium resultant of observing each treated animal.The result shows that preparation of the present invention (round trip flight people board bone density improving capsule) has the effect of the animal bone of increasing density.
Table 1: the present invention to the influence of rat bone density and calcium content of bone (
± s, n=10)
Notes: * and model control group compare P, and < 0.05, * * and matched group be P < 0.01 relatively
From table, learn, in selected dosage range, among the present invention dose groups and high dose all can increase fl bone density and right femur bone calcium (P 0.05, P 0.01), and femur weight is not influenced.Be that round trip flight people board bone density improving capsule has the effect of the animal bone of increasing density.
Acute toxicity test
Carry out acute toxicity test, bone marrow cell micronucleus test, sperm malformation test, Salmonella reversion test and 30d feeding trial according to toxicological evaluation program and method.Result: its mouse oral MTD>20.0g/kg.BW (recommended amounts is 0.05g/kg.bw), belong to non-poisonous material; Bone marrow cell micronucleus test, sperm malformation test and Salmonella reversion test result are all negative; The equal no abnormality seen of each item index in 30 feeding trials.Following table explanation the present invention does not have obvious influence to organ weights and the organ coefficient of animal.Acute toxicity test proves that pharmaceutical composition of the present invention is not observed toxicity.
Table 2: the present invention to the influence of Rats Organs and Tissues weight (
± s, n=10)
Visible by table 2, the liver,kidney,spleen of each dose groups animal, the weight of gonad and matched group comparing difference not statistically significant explain that the present invention's organ weights and organ coefficient to animal under this experimental condition all do not have obvious influence.
Pharmaceutical composition of the present invention is bone density improving effectively, and does not observe toxic reaction through the acute toxic reaction test, explains that pharmaceutical composition of the present invention is safely and effectively.
According to foregoing of the present invention,,, can also make modification, replacement or the change of other various ways not breaking away under the above-mentioned basic fundamental thought of the present invention prerequisite according to the ordinary skill knowledge and the customary means of this area.Below, foregoing of the present invention is remake further detailed description through the specific embodiment of embodiment form.But should this be interpreted as that the scope of the above-mentioned theme of the present invention only limits to following instance.All technology that realizes based on foregoing of the present invention all belong to scope of the present invention.
Claims (4)
1. pharmaceutical composition with bone density improving function, it is characterized in that: with calcium carbonate, glucosamine hydrochloride, chondroitin sulfate, Herba Epimedii extract, Radix Achyranthis Bidentatae extract, phosphopeptide caseinate is the oral formulations that active ingredient is processed; Wherein the active ingredient percentage by weight consists of: calcium carbonate 10-40%, glucosamine hydrochloride 5-30%, chondroitin sulfate 5-20%, Herba Epimedii extract 5-30%, Radix Achyranthis Bidentatae extract 3-10%, phosphopeptide caseinate 3-15%.
2. the pharmaceutical composition with bone density improving function according to claim 1, it is characterized in that: primary raw material consists of: calcium carbonate 20-50%, glucosamine hydrochloride 10-40%, chondroitin sulfate 10-30%, Herba Epimedii extract 10-40%, Radix Achyranthis Bidentatae extract 5-25%, phosphopeptide caseinate 10-30%.
3. pharmaceutical composition according to claim 2 is characterized in that: corresponding adjuvant is processed tablet, capsule, granule or oral liquid in addition.
According to the described pharmaceutical composition of claim 1-3 preparation have the bone density improving function medicine and health food in use.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012101517622A CN102657842A (en) | 2012-05-17 | 2012-05-17 | Medicinal composition with function of increasing bone density and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012101517622A CN102657842A (en) | 2012-05-17 | 2012-05-17 | Medicinal composition with function of increasing bone density and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102657842A true CN102657842A (en) | 2012-09-12 |
Family
ID=46767509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012101517622A Pending CN102657842A (en) | 2012-05-17 | 2012-05-17 | Medicinal composition with function of increasing bone density and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102657842A (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102885304A (en) * | 2012-10-12 | 2013-01-23 | 中科乐仁（北京）科技发展有限公司 | BMD (bone mineral density)-increased health food composite and preparation method thereof |
| CN102948760A (en) * | 2012-11-23 | 2013-03-06 | 西安泰科迈医药科技有限公司 | Health-care product for increasing bone density and preparation method thereof |
| CN103039997A (en) * | 2013-01-11 | 2013-04-17 | 湖南映荷生物科技有限公司 | Health-care food composition for increasing bone mineral density and preparation method |
| CN103053902A (en) * | 2012-12-21 | 2013-04-24 | 杭州海王生物工程有限公司 | A compound tablet with a high content of chondroitin sulfate and a preparation method thereof |
| CN103110744A (en) * | 2013-03-20 | 2013-05-22 | 吉林华康食元生物科技有限公司 | Traditional Chinese medical health-care preparation for increasing bone density and preparation method thereof |
| CN104127861A (en) * | 2014-07-31 | 2014-11-05 | 漳州片仔癀药业股份有限公司 | Pharmaceutical composition with bone mineral density increasing function and preparation method thereof |
| CN105726604A (en) * | 2016-03-15 | 2016-07-06 | 双飞人制药股份有限公司 | Pharmaceutical composition with bone mineral density increasing function and preparation method of pharmaceutical composition |
| CN105996052A (en) * | 2016-07-01 | 2016-10-12 | 福建省力菲克药业有限公司 | Healthcare food for improving bone mineral density and preparation method thereof |
| CN106177908A (en) * | 2015-05-06 | 2016-12-07 | 北京宝德润生医药科技发展有限公司 | A kind of have compositions increasing bone substance density improving function and preparation method thereof |
| CN111068044A (en) * | 2020-01-06 | 2020-04-28 | 新疆华圣元医药科技有限公司 | Pharmaceutical composition with bone mineral density increasing effect and preparation thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101015682A (en) * | 2007-02-01 | 2007-08-15 | 甘肃奇正藏药有限公司 | Medicine composition with compact bone substance density improving function, preparing process and quality controlling means thereof |
| CN101711786A (en) * | 2009-12-18 | 2010-05-26 | 威海康博尔生物药业有限公司 | Preparation used for relieving osteoarthropathy and enhancing immunity |
-
2012
- 2012-05-17 CN CN2012101517622A patent/CN102657842A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101015682A (en) * | 2007-02-01 | 2007-08-15 | 甘肃奇正藏药有限公司 | Medicine composition with compact bone substance density improving function, preparing process and quality controlling means thereof |
| CN101711786A (en) * | 2009-12-18 | 2010-05-26 | 威海康博尔生物药业有限公司 | Preparation used for relieving osteoarthropathy and enhancing immunity |
Non-Patent Citations (2)
| Title |
|---|
| 杨国夫等: "牛膝提取物对去卵巢大鼠骨密度、骨转换及I型胶原蛋白表达的影响", 《中国骨质疏松杂志》 * |
| 生庆海等: "酪蛋白磷酸肽(CPP)对生长期大鼠骨密度的影响", 《中国乳品工业》 * |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102885304A (en) * | 2012-10-12 | 2013-01-23 | 中科乐仁（北京）科技发展有限公司 | BMD (bone mineral density)-increased health food composite and preparation method thereof |
| CN102948760A (en) * | 2012-11-23 | 2013-03-06 | 西安泰科迈医药科技有限公司 | Health-care product for increasing bone density and preparation method thereof |
| CN103053902A (en) * | 2012-12-21 | 2013-04-24 | 杭州海王生物工程有限公司 | A compound tablet with a high content of chondroitin sulfate and a preparation method thereof |
| CN103039997A (en) * | 2013-01-11 | 2013-04-17 | 湖南映荷生物科技有限公司 | Health-care food composition for increasing bone mineral density and preparation method |
| CN103110744A (en) * | 2013-03-20 | 2013-05-22 | 吉林华康食元生物科技有限公司 | Traditional Chinese medical health-care preparation for increasing bone density and preparation method thereof |
| CN104127861A (en) * | 2014-07-31 | 2014-11-05 | 漳州片仔癀药业股份有限公司 | Pharmaceutical composition with bone mineral density increasing function and preparation method thereof |
| CN104127861B (en) * | 2014-07-31 | 2016-08-17 | 漳州片仔癀药业股份有限公司 | A kind of have pharmaceutical composition increasing bone density effect and preparation method thereof |
| CN106177908A (en) * | 2015-05-06 | 2016-12-07 | 北京宝德润生医药科技发展有限公司 | A kind of have compositions increasing bone substance density improving function and preparation method thereof |
| CN105726604A (en) * | 2016-03-15 | 2016-07-06 | 双飞人制药股份有限公司 | Pharmaceutical composition with bone mineral density increasing function and preparation method of pharmaceutical composition |
| CN105996052A (en) * | 2016-07-01 | 2016-10-12 | 福建省力菲克药业有限公司 | Healthcare food for improving bone mineral density and preparation method thereof |
| CN111068044A (en) * | 2020-01-06 | 2020-04-28 | 新疆华圣元医药科技有限公司 | Pharmaceutical composition with bone mineral density increasing effect and preparation thereof |
| CN111068044B (en) * | 2020-01-06 | 2022-03-08 | 新疆华圣元医药科技有限公司 | Pharmaceutical composition with bone mineral density increasing effect and preparation thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102657842A (en) | Medicinal composition with function of increasing bone density and application thereof | |
| CN102327420B (en) | Chinese medicinal composition for setting bones and replenishing muscles and ligaments | |
| CN104352608B (en) | A kind of benefiting QI for activating blood circulation, hard masses softening and resolving, the Chinese medicine and preparation method thereof of removing toxic substances pain relieving | |
| CN101292739B (en) | Health food having function of increasing bone substance density | |
| CN103330197A (en) | Health-care food for improving osteoporosis | |
| CN102274370A (en) | Traditional Chinese medicine composition for treating fracture | |
| CN111097032A (en) | Health product for preventing and treating osteoporosis and preparation method thereof | |
| CN102626463A (en) | Natural medicine compound for increasing bone mineral density and preventing and treating osteoporosis | |
| CN102813783A (en) | Pure traditional Chinese medicine capsule for treating gout | |
| CN109906084B (en) | Calcium supplement composition capable of reducing risk of hypercalcemia and application thereof | |
| CN108719970A (en) | A kind of composition, health products and preparation method thereof comprising it increasing bone density | |
| CN106177922A (en) | A kind of composite collagen gel increasing bone density, prevention senile osteoporosis and preparation method thereof | |
| CN110897152A (en) | Composition and capsule for increasing bone mineral density and preparation method thereof | |
| CN114558088B (en) | Mongolian medicine compound for treating primary osteoporosis and application thereof | |
| CN108095114A (en) | A kind of Chinese medicine and health food for increasing bone density and preparation method thereof | |
| WO2022104712A1 (en) | Compound composition having effect of promoting bone health, preparation method therefor and application thereof | |
| CN105770358A (en) | Traditional Chinese medicine composition for treating geriatric fracture and method for preparing traditional Chinese medicine composition | |
| CN101444552B (en) | Chinese medicinal preparation for treating osteoporosis | |
| CN103610740A (en) | Calcium chelate | |
| CN112137087A (en) | Composition and health product for strengthening bones and supplementing calcium and preparation method thereof | |
| CN105232642A (en) | Traditional Chinese medicine combination capable of promoting fracture healing | |
| CN104491292A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating osteoporosis | |
| CN111109603A (en) | Food formula with effects of tonifying kidney and strengthening bones and preparation method | |
| CN105726604A (en) | Pharmaceutical composition with bone mineral density increasing function and preparation method of pharmaceutical composition | |
| CN100493555C (en) | Medicine for treating the pain of neck, shoulder, waist and leg |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120912 |